Nivolumab Injection [Opdivo]

CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma

A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors

Checkpoint Inhibitors and SBRT for MCRPC

Safety and Tolerability of TAR-200 and Nivolumab in Subjects With Muscle-Invasive Bladder Cancer

An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Phase I Study VG2025 as a Single Agent and in Combination Therapy With Nivolumab in Subjects With Advanced Malignant Solid Tumors

Neoadjuvant and Adjuvant Nivolumab in HCC Patients Treated by Electroporation

Nivolumab Combined With Chemotherapy in the Treatment of Primary Tracheal Squamous Cell Carcinoma

Melanoma Metastasized to the Brain and Steroids

Combined Immunotherapy and Radiosurgery for Metastatic Colorectal Cancer

MTG201 Plus Nivolumab in Patients With Relapsed Pleural Mesothelioma

Addition of Nivolumab to Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive DLBCL at Lymphodepletion